Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program.
PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All Participants | All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| All participants | Other | All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with Primary plan type | The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance. | Index date defined as the date of enrollment in the PSS program |
| Measure | Description | Time Frame |
|---|---|---|
| Age | Age information of patients enrolled in the brolucizumab PSS program was reported | Index date defined as the date of enrollment in the PSS program |
| Gender | Gender information of patients enrolled in the brolucizumab PSS program was reported |
Not provided
Inclusion Criteria:
Exclusion Criteria:
• None
Not provided
Not provided
The study included patients with wet AMD
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | East Hanover | New Jersey | 07936-1080 | United States |
Not provided
| Label | URL |
|---|---|
| Results for CRTH258AUS18 from the Novartis Clinical Trials Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Index date defined as the date of enrollment in the PSS program |
| Patient region (by state) | Distribution of patients across US states | Index date defined as the date of enrollment in the PSS program |
| Provider region (by state) | Number of providers and their distribution across US states | Index date defined as the date of enrollment in the PSS program |
| Insurance coverage | The insurance coverage details for all the patients with wet AMD was reported | Index date defined as the date of enrollment in the PSS program |
| Number of patients with Secondary plan type | The secondary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The secondary plan included commercial, government or other insurance | Index date defined as the date of enrollment in the PSS program |
| Disease Status | The eye disease status of all the patients were reported. Disease status was categorized as Right eye, left eye, or bilateral | Index date defined as the date of enrollment in the PSS program |
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided